Max Tejada

Max Tejada has extensive experience in the biotechnology industry, with their most recent role being Vice President and Head of Analytical Development at Sana Biotechnology, Inc. Max previously held senior positions at Kite Pharma, AstraZeneca, Gilead Sciences, and Genentech, where they led teams focused on the development and validation of bioassays and analytical methods for large molecule and novel biotherapeutics. Max also has a strong background in training, technical support, and regulatory filings. Max began their career as a PhD candidate at Queen's University.

Max Tejada obtained a PhD in Biochemistry from Queen's University from 1994 to 2000. Prior to that, they completed an MSc in Biochemistry from the University of Windsor from 1992 to 1994. Max also holds a BSc in Biochemistry from Laurentian University/Université Laurentienne, which they received from 1985 to 1989. Additionally, Max Tejada has an MBA in Business from Notre Dame de Namur University; however, there is no specific information regarding the duration or completion of this degree. Max also obtained a certification in Leading Strategic Growth from Columbia Business School in 2019.